Thursday, March 30, 2023

Time: 10:00-11:00 AM EST

In rare disease, compassionate use and Expanded Access Programs (EAPs) are becoming increasingly more common. As sponsors grapple with the unique needs of rare disease patients who may not have access to an approved therapy, impact of Expanded Access Programs and how or where they may fit within the larger context of accessible clinical trial landscape becomes more pressing. Experts within patient advocacy, CROs, and industry will provide insights into important considerations for all these stakeholders as they develop and implement EAPs.


Will Maier

Vice President, Center for Rare Diseases, ICON plc


Deborah Gelinas

Executive Director, Neuromuscular, argenx

Jack Johnson

Executive Director & Cofounder, Fabry Support & Information Group

Ray Kaczmarek

Senior Director, Project Operations, Commercialisation & Outcomes, ICON plc